Fig. 6: In vivo STAT3-silencing approach mitigates the evolution of immunopathological disorders in vFLIP mice.

A Pathological score of lungs of vFLIP mice (untreated, n = 6; sh-scramble, n = 5; sh-STAT3, n = 5) by H&E staining. Scale bar, 200 μm. B Flow cytometry analysis of myeloid cells (CD11b⁺ cells), mononuclear phagocytes (Ly6C⁺ cells), neutrophils (Ly6G⁺ cells), B (B220⁺ cells), and T (CD3⁺ cells) lymphocytes isolated from lungs of vFLIP mice (untreated, n = 6; sh-scramble, n = 5; sh-STAT3, n = 5) or WT mice (n = 5). C Lymphocytes (B cells: B220⁺ cells; T cells: CD3⁺ cells) and macrophages (F4/80⁺ cells) quantification in spleens of vFLIP mice (untreated, n = 6; sh-scramble, n = 5; sh-STAT3, n = 5) by H&E staining. Scale bar, 400 μm. D Flow cytometry analysis in peripheral blood of myeloid cells (CD11b⁺ cells), mononuclear phagocytes (Ly6C⁺ cells), neutrophils (Ly6G⁺ cells), B (B220⁺ cells), and T (CD3⁺ cells) lymphocytes in vFLIP mice (untreated, n = 6; sh-scramble, n = 5; sh-STAT3, n = 5) or WT mice (n = 5). E Analysis of cytokines levels in serum of WT (n = 5), sh-scramble (n = 5), or sh-STAT3 (n = 5) vFLIP mice. Data are reported as mean ± S.E.M. *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001 by Mann–Whitney test.